What one share of Turn Therapeutics holds
Our business is dependent on successful clinical trials of our products as well as FDA clearances/approvals of our products. We have three FDA clearances for medical devices, two of which were obtained by the fourth quarter of 2017.
Turn Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.29 |
|---|---|
| Cash and investments | $0.33 |
| Debt | $0.20 |
| Book value | $0.02 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$0.07 | — | — | — | −$0.01 |
| 2025 | — | −$0.12 | — | — | — | $0.16 |
Common questions about Turn Therapeutics
How much does one share of Turn Therapeutics earn?
Over the last 12 months, Turn Therapeutics lost $0.29 for each share.
Does Turn Therapeutics pay a dividend?
Turn Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Turn Therapeutics’s book value per share?
Turn Therapeutics’s book value is $0.02 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Turn Therapeutics have?
Each share of Turn Therapeutics has $0.33 of cash and investments and $0.20 of debt, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.